Metastatic Colorectal Cancers Recruiting Phase 1 / 2 Trials for Bevacizumab (DB00112)

Also known as: Colorectal cancer metastatic / Metastatic Colorectal Cancer

IndicationStatusPhase
DBCOND0063579 (Metastatic Colorectal Cancers)Recruiting1 / 2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT03829410Onvansertib in Combination With FOLFIRI and Bevacizumab for Second Line Treatment of Metastatic Colorectal Cancer Patients With a Kras MutationTreatment
NCT03376659Durvalumab Plus CV301 With Maintenance Chemotherapy in Metastatic Colorectal or Pancreatic AdenocarcinomaTreatment